Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Pharm Sci ; 100(9): 3854-61, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21607954

RESUMO

We previously showed that oseltamivir, a prodrug of the influenza virus neuraminidase inhibitor Ro 64-0802, is a substrate of proton-coupled oligopeptide transporter (PEPT1), and its intestinal absorption in rats is markedly inhibited by administration with milk. To investigate the importance of PEPT1 for oseltamivir absorption in humans, and the characteristics of the drug-milk interaction, a crossover clinical study was conducted in healthy volunteers, who received 75 mg of oseltamivir with 400 mL of water or milk. Milk significantly reduced the maximum plasma concentration (C(max) ) and the area under the plasma concentration-time curve from 0 to 2 h (AUC(0-2) ) of both oseltamivir and Ro 64-0802 (oseltamivir, 68.9% and 34.5%; Ro 64-0802, 69.5% and 14.2%, respectively, vs. water), but had no significant effect on the apparent terminal half-life (t(1/2) ) or AUC(0-∞) . Urinary recovery of oseltamivir and Ro 64-0802 was significantly reduced to 77.5% of the control by milk. The early reduction of oseltamivir absorption might be through the PEPT1 inhibition by milk peptides. However, the extent of interaction in humans was limited as compared with that in rats, possibly because of species difference in the PEPT1 expression and its contribution. This might be the first report suggesting the clinical drug-food interaction via PEPT1.


Assuntos
Antivirais/farmacocinética , Leite , Oseltamivir/farmacocinética , Acetamidas/sangue , Acetamidas/farmacocinética , Acetamidas/urina , Adulto , Animais , Antivirais/sangue , Antivirais/urina , Área Sob a Curva , Estudos Cross-Over , Interações Alimento-Droga , Meia-Vida , Humanos , Oseltamivir/sangue , Oseltamivir/urina , Valores de Referência
2.
Chem Pharm Bull (Tokyo) ; 50(11): 1511-3, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12419921

RESUMO

An improved synthetic route of OPC-29030, the platelet adhesion inhibitor, was established via the diastereoselective oxidation of a chiral non-racemic sulfide (R)-5 to (S(S))-6 by the catalytic oxidation using VO(acac)(2) and cumene hydroperoxide (CHP) in the presence of MS4A. Under the current condition, the diastereoselectivity was not influenced by the presence of moisture, and moderate to high selectivity (72% de) was obtained at -30 degrees C. The obtained sulfoxide, which diastereomeric excess was easily raised by the recrystallization, could successfully lead to OPC-29030.


Assuntos
Adesividade Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/síntese química , Sulfetos/síntese química , Imidazóis , Oxirredução , Inibidores da Agregação Plaquetária/química , Quinolonas , Estereoisomerismo , Sulfetos/química , Compostos de Enxofre
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA